PRF Technologies (PRFX) Net Income towards Common Stockholders (2020 - 2024)
PRF Technologies' (PRFX) quarterly Net Income towards Common Stockholders came in at -$7.6 million in Q2 2024, down 204.12% YoY from $7.3 million in Q3 2023, and down 30.63% on a QoQ basis from -$5.8 million in Q1 2024.
PRF Technologies (PRFX) Net Income towards Common Stockholders (2020 - 2024) Analysis & Trends
PRF Technologies (PRFX) has 5 years of Net Income towards Common Stockholders data on file, last reported at -$7.6 million in Q2 2024.
- Quarterly Net Income towards Common Stockholders fell 204.12% year-over-year to -$7.6 million in Q2 2024, while the trailing twelve-month figure through Dec 2025 was -$7.6 million (up 68.54% YoY) and the FY2025 annual result came in at -$5.0 million, up 66.16% from the prior year.
- Net Income towards Common Stockholders declined to -$7.6 million in Q2 2024, from -$5.8 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$700000.0 in Q3 2020 to a low of -$10.7 million in Q4 2023.
- A 5-year average of -$3.7 million and a median of -$2.2 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders surged 31.46% — and 2024, when it plunged 204.12%.
- Tracing PRFX's Net Income towards Common Stockholders over 5 years: stood at -$4.2 million in 2020, then plunged by 65.42% to -$6.9 million in 2021, then declined by 28.75% to -$8.9 million in 2022, then dropped by 21.01% to -$10.7 million in 2023, then climbed by 29.24% to -$7.6 million in 2024.
- The last three Net Income towards Common Stockholders figures came in at -$7.6 million (Q2 2024), -$5.8 million (Q1 2024), and -$10.7 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | PRF Technologies | 654,452.72 | -3.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -7.60 Mn |
| Mar 31, 2024 | -5.82 Mn |
| Dec 31, 2023 | -10.74 Mn |
| Sep 30, 2023 | -1.60 Mn |
| Jun 30, 2023 | -2.50 Mn |
| Mar 31, 2023 | -2.66 Mn |
| Dec 31, 2022 | -8.88 Mn |
| Sep 30, 2022 | -2.34 Mn |
| Jun 30, 2022 | -2.08 Mn |
| Mar 31, 2022 | -1.91 Mn |
| Dec 31, 2021 | -6.89 Mn |
| Sep 30, 2021 | -2.00 Mn |
| Jun 30, 2021 | -1.88 Mn |
| Mar 31, 2021 | -2.04 Mn |
| Dec 31, 2020 | -4.17 Mn |
| Sep 30, 2020 | -700,000.00 |
| Jun 30, 2020 | -969,000.00 |
| Mar 31, 2020 | -1.59 Mn |